



**IPMG**

International Pharmaceutical Manufacturers Group

# APAC from the Indonesian Perspective

Presented by:

**Parulian Simanjuntak - Executive Director of IPMG**

at 2nd Indonesia – Japan Symposium

Wednesday, May 21st, 2014

Novotel Hotel Mangga Dua

---



**IPMG**

International Pharmaceutical Manufacturers Group

# History

- Invitation to attend the first APAC in Tokyo in March 2012: Asia Partnership Conference of Pharmaceutical Associations (APCPA)
- Initiative developed in 2010 for 2011, but Fukushima tragedy came and the conference was postponed to 2012



**IPMG**

International Pharmaceutical Manufacturers Group

# Objective of APAC

Building up collaborative activities of pharma-associations across the Asia considering the wide diversity of economic/medical conditions and industry issues across the region.



**IPMG**

International Pharmaceutical Manufacturers Group

# Why Participating in APAC?

Status of pharma industry in Indonesia:

1. Still at the formulation stage
2. No real R&D activities
3. Very low volume of clinical trials conducted in Indonesia



**IPMG**

International Pharmaceutical Manufacturers Group

## We Should Not Miss the Train!

Indonesia can't afford not participating in such project:

1. To develop Asia as an economic center;
2. With a favorable environment to develop and invent innovative drugs from Asia for Asian;
3. and ultimately to improve healthcare situation and condition in Asia.



**IPMG**

International Pharmaceutical Manufacturers Group



**IPMG**

International Pharmaceutical Manufacturers Group

# Mission of APAC

**To expedite the launch of innovative medicines for the people in Asia**

- APAC 2012: We people living in Asia to change Asia from Inside
- APAC 2013: Toward a cooperation with government and academia
- APAC 2014: Progressing towards a Strategic Roadmap for a Framework of Drug Discovery and Development in Asia



**IPMG**

International Pharmaceutical Manufacturers Group



**IPMG**

International Pharmaceutical Manufacturers Group

# Working Groups

1. Expert Working Groups:
  - a) Regulations and Approval
  - b) Drug Discovery Alliance
2. Steering Committee

## Mode of communications:

- Teleconferences (all groups)
- Meetings during symposia and conferences on drug discovery



**IPMG**

International Pharmaceutical Manufacturers Group

# Achievements so far..

What started as:  
'Let's see how  
this would work  
out' and  
'Identify  
differences and  
discuss common  
ground'  
(2012 – 2013)

HAS ALREADY  
PRODUCED

## Achievements:

- 'A Roadmap for recommendations to the regulatory authorities for early product approval taking into account variations in each economy' (2014)
- Drug-discovery open innovation platform thru BGA collaboration





**IPMG**

International Pharmaceutical Manufacturers Group

# Participants

## Indonesia

2012 –	Parulian Simanjuntak (IPMG)
2013 –	Parulian Simanjuntak (IPMG)
	Philip Tan (PT Eisai Indonesia)
2014 -	Siti Sari Septiani (Binfar)
	Tia Eka Wulansari (Binfar)
	Parulian Simanjuntak (IPMG)

## Other ASEAN Participants from The Government

1. Ann Ling Tan, MoH, Malaysia
2. Aye Nyein Myat, FDA-MoH, Myanmar
3. Wynn Ko Ko, Ministry of Industry, Myanmar
4. Boonchai Somboonsok, FDA, Thailand
5. Prapassorn Thanaphollert, Bureau of Drug Control, Thailand
6. Truong Quoc Cuong, DAV, MoH, Vietnam
7. Chu Dang Trung, DAV, MoH, Vietnam



**IPMG**

International Pharmaceutical Manufacturers Group

# RECOMMENDATION

for the Government of Republic of Indonesia

To support for the success of APAC by  
attending APAC meetings



Handwritten signature in red ink, reading "Karlson".